MEDVi
Broad Access$179–$349/month
Available in 49 states with injectable and tablet GLP-1 options.
Visit MEDVi →Pros
- Available in 49 states — broadest coverage of any GLP-1 telehealth platform
- LegitScript certified
- Offers both injectable and tablet formulations of semaglutide and tirzepatide
- 11,000+ Trustpilot reviews at 4.4 stars
- No long-term contracts; money-back guarantee
- 24/7 messaging and unlimited telehealth consultations included
Cons
- FDA warning letter (Feb 2026) for misbranding — compounded medication marketed without clearly attributing the dispensing pharmacy
- Refill pricing ($299/month) higher than introductory rate ($179/month)
- Compounded medications are not FDA-approved as finished products
Details
- Medications offered
- compounded semaglutide, compounded tirzepatide
- State availability
- All 50 states
- Affiliate network
- katalys
- Data verified
- 2026-04-14